Table 2 Summary of incidence of CRS and ICANS after CAR-T cell therapies
From: Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Name of CART therapies | Class of CART | Disease | CRS: All grades | CRS: Grade >  = 3 | Neurotoxicity All | Neurotoxicity Grade =  > 3 | References |
|---|---|---|---|---|---|---|---|
ABECMA | BCMA-BBz | Multiple myeloma | 84% | 5% | 18% | 3% | Munshi (2021) [26] |
BREYANZI | CD19-BBz | Large B-cell lymphoma | 49% | 1% | 12% | 4% | Kamdar (2022) [27] |
CARVYKTI | BCMA-BBz | Multiple myeloma | 95% | 4% | 21% | 9% | Berdeja (2021) [28] |
KYMRIAH | CD19-BBz | Large B-cell lymphoma | 58% | 22% | 26% | 15% | Schuster (2019) [29] |
TECARTUS | CD19-BBZ | B-cell acute lymphoblastic leukemia | 89% | 24% | 60% | 50% | Shah (2021) [30] |
YESCARTA | CD19-28z | Large B-cell lymphoma | 92% | 6% | 60% | 21% | Locke (2022) [31] |